Q3 2024 MDxHealth SA Earnings Call Transcript
Key Points
- MDxHealth SA (MDXH) reported a 21% year-over-year revenue growth for Q3 2024, with revenues reaching $23.3 million.
- The company raised $40 million in gross proceeds during the quarter, strengthening its cash position to $53.5 million.
- MDxHealth SA increased its 2024 revenue guidance for the third consecutive quarter, now expecting $87 to $89 million, reflecting confidence in their diagnostic value.
- The company achieved a 30% growth in total billable test volume, with tissue-based tests growing by 36% and liquid-based tests by 24% year-over-year.
- MDxHealth SA is on track to achieve adjusted EBITDA positivity in the first half of 2025, supported by strong revenue growth and operating discipline.
- Gross margins declined to 61.2% in Q3 2024 from 64.9% in Q3 2023, primarily due to a backlog of select Medicare cases recognized in the previous year.
- Operating loss increased to $6.1 million in Q3 2024 from $4.6 million in Q3 2023, driven by clinical study expenses and sales incentive compensation.
- The company faces challenges in expanding commercial payer coverage, with ongoing efforts required to improve ASP growth.
- Despite strong growth, MDxHealth SA has not expanded its sales organization, which could limit future growth potential if not addressed.
- The company acknowledges the potential impact of seasonality and fewer business days in Q4, which could affect revenue growth.
Good day and welcome to MDX Health third quarter, 2024 earnings call. (Operator Instructions). After today's presentation, there will be an opportunity to ask questions, ask a question. (Operator Instructions). Now I let the conference over to Michael McGarrity Chief Executive Officer. Please go ahead.
Thanks Keith and thank you all for joining us for our third quarter, 2024 earnings conference call for MBXL with me today is Ron Kalfus Chief Financial Officer the third quarter marked another period of solid performance for our company as demonstrated by year over year revenue growth of 21% or when adjusted for select revenue backlog in the third quarter of last year, following our Medicare coverage, an effective year over year revenue growth rate of 27% based on consistent commercial execution and operating discipline.
We believe that our growing leadership position in urology precision Diagnostics will position us to generate strong and sustainable revenue growth of at least 20% and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
